A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 28 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2018.
- 10 Jun 2017 Biomarkers information updated